Stem Cell Authority Announces Plan to Develop Immune Cell Activity Detection to Help Enhance Resistance to Diseases and Infection

^{SHANGHAI, Nov. 18, 2021 – Stem Cell Authority, Ltd. (OTC Pink: SCAL)(the“Company”), a clinical-stage biopharmaceutical company committed to the research and development of immune system disease treatments using small molecules and stem cell technology, announced today it has initiated plans for an immune cell activity detection program by entering into an agreement with Shanghai Mingda Biotech Co., Ltd. to provide exact measurements of immune cell activity differences among healthy people, subhealthy people and cancer patients.}

^{When our immune system functions properly it detects threats, such as bacteria, parasites, and viruses, and it triggers an immune response to destroy them. Our immune system can broadly be divided into two parts: innate and adaptive. Innate immunity is the natural protection that we are born with and our first line of defense to combat infection. Upon detecting an infection, our innate response acts quickly to try and flush out the invader by producing extra mucus or cranking up the thermostat to blast it with a fever. Adaptive immunity is protection that we gain throughout life as we are exposed to diseases or protected against them from vaccinations. The adaptive system spots an enemy and produces the specific weapons — or antibodies — that are required to destroy and eliminate the invader from the body.}

^{Stem Cell Authority will work closely with Shanghai Mingda Biotech, establishing central laboratories in major cities in China, retrieving specimen, providing qualified hospitals with detecting instruments and diagnosis kits.}

^{Forward-Looking Statement Disclaimer}

^{This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law.}